Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Accumulated Expenses (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Accumulated Expenses for 6 consecutive years, with $13.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 35.75% to $13.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.6 million through Dec 2025, down 35.75% year-over-year, with the annual reading at $13.6 million for FY2025, 35.75% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $13.6 million at Relay Therapeutics, down from $25.1 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $33.2 million in Q3 2024, with the low at $8.9 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $21.8 million, with a median of $22.2 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses surged 135.36% in 2021, then plummeted 35.75% in 2025.
  • Over 5 years, Accumulated Expenses stood at $13.6 million in 2021, then surged by 67.46% to $22.7 million in 2022, then tumbled by 34.41% to $14.9 million in 2023, then surged by 42.62% to $21.2 million in 2024, then tumbled by 35.75% to $13.6 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $13.6 million, $25.1 million, and $23.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.